Key facts, as of
As of November 2, 2026, Gilead Sciences (GILD) trades at $170.75, up 42.5% over the past year. Its 52-week range runs from $116.88 to $175.65; the price is 2.8% below that high. It is 2.8% below its all-time high of $175.65, reached in October 2026. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +230.2%, against +316.3% for the S&P 500 (SPY). It sits 21.9% above its 200-day average of $140.13, and its 50-day average is above the 200-day too: an uptrend on both averages. Its 30-day volatility is 28.7% annualized, which we rate medium risk. It has a dividend yield of 1.92%.
Cite: Portfolio Terminal, "Gilead Sciences (GILD) stock analysis", 2026-11-02. https://portfolio-terminal.com/analyse/gild
Where it trades today
trading 92% of the way up its 52-week range
How the price has moved
How far it is from its record
Gilead Sciences (GILD) is 2.8% below its all-time high of $175.65, reached in October 2026. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +230.2%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- GILD closes above its 50-day average ($151.37), and the 50-day sits above the 200-day ($140.13): on both averages the chart reads as an uptrend.
- At $170.75, GILD is 2.8% below its 1-year high of $175.65, set on October 30, 2026, and 49.8% above its 1-year low of $114.02 (October 31, 2025).
- Over the past month GILD rose 18.0%, from $144.74 to $170.75.
- GILD's 30-day volatility, 28.7% a year, works out to a typical daily move of about 1.8%.
- Yahoo Finance puts its beta at 0.37: over five years of monthly returns, GILD moved about 0.37% for each 1% move of the S&P 500.
What would change the read
- A close under the 50-day average, $151.37 (−11.4% from the last close), would turn the read to a pullback; under the 200-day, $140.13 (−17.9%), the longer rise is in question.
- A close above $175.65 (+2.9%) would be a new 1-year high; below $114.02 (−33.2%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for GILD, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under drug manufacturers—general among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for GILD by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for GILD. Last refresh: Nov 2, 2026, 7:10 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Drug Manufacturers—General.
What Gilead Sciences does
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.…
Employees
17,000
Industry
Drug Manufacturers - General
Headquarters
Foster City, United States
What analysts expect
GILD carries a buy consensus from 26 analysts, with an average price target of $172.50 versus $170.75 today (+1.0%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
GILD generated $30.99B in trailing revenue (6.8% year over year), with a -12.5% net margin, and $10.68B of free cash flow, against $18.28B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $29.44B | $23.21B | $11.70B | $8.51B | $6.84 | $9.46B |
| 2024 | $28.75B | $22.50B | $10.60B | $480.00M | $0.38 | $10.30B |
| 2023 | $27.12B | $20.62B | $8.84B | $5.67B | $4.54 | $7.42B |
| 2022 | $27.28B | $21.62B | $10.97B | $4.59B | $3.66 | $8.34B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
GILD is in 22 of the 54 ETFs we track. It weighs most in XLV: 3.02% of the fund, holding #8 of 62.
Famous investors who hold it
GILD is in the latest 13F of 2 of the 15 famous investors we follow. Renaissance Technologies (Founded by Jim Simons) holds the most of it: 0.39% of the portfolio, position #35 of 2,931, as of Q2 2026.
How its figures compare with those peers
Companies in the same industry
GILD beside the other companies Yahoo Finance files under drug manufacturers—general among the assets we track (LLY, JNJ, ABBV, largest first).
GILDyou are here$170.75$211.79B
LLYEli Lilly and Company$1406.76$1.25T
JNJJohnson & Johnson$269.63$649.10B
ABBVAbbVie Inc.$288.60$509.98BWhat the chart is saying
In an uptrend, 2.8% under its 1-year high with no resistance above.
uptrend- Price is 12.8% above its 50-day average and 21.9% above its 200-day.
- The 50-day crossed above the 200-day on 2026-08-27 (a “golden cross”).
- RSI at 74 is overbought: strong momentum, and stretched.
- Nothing above has stopped it this year; the nearest floor is $153.38 (-10.2%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
What is the risk level of GILD?
Based on 30-day volatility of 28.7%, GILD has MEDIUM risk. Its beta of 0.37 means it has swung less than the S&P 500 over the last five years.
Does GILD pay dividends?
Yes, Gilead Sciences has a dividend yield of 1.92%.
How far is GILD from its all-time high?
Gilead Sciences is 2.8% below its all-time high of $175.65, reached in October 2026. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +230.2%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold GILD?
22 of the 54 popular ETFs we track hold Gilead Sciences. The largest weights: XLV (3.02%), CNDX (0.85%), QQQ (0.84%), QQQM (0.84%) and VIG (0.82%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is GILD?
0.28%, as of September 30, 2026: GILD is holding #62 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $2.81 in Gilead Sciences.
Which famous investors own GILD?
Renaissance Technologies (0.39% of Founded by Jim Simons's 13F) and Ray Dalio (0.15% of Bridgewater Associates's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for GILD?
The average analyst price target for Gilead Sciences (GILD) is $172.50 based on 26 analyst estimates, about 1.0% above the current price of $170.75. The published range runs from $131.00 to $200.00.
How much revenue does GILD generate?
Gilead Sciences reported $30.99B in trailing twelve-month revenue. Revenue growth is running at 6.8% year over year. Net margin sits at -12.5%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare GILD with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.